Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles